Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality.
Keywords: Asthma; Bronchiolitis; Elderly; Eosinophilia; Epitope; Fusion; Immunization; Infants; Neutralization; Pneumonia; Protein conformation; RSV; Structure-based vaccine design; Subunit vaccine; Th2; Vaccination; Vaccine vector; Vaccine-enhanced illness; Wheezing.
Published by Elsevier Ltd.